Table 1

General characteristics of patients (N = 174)

CharacteristicsSex (M/F)Age, y (SE)No. (%)IPSS, mean
WHO classification 
MDS, n = 94 
        Low grade, n = 66     
        RA/RCMD (20) 14/6 57 ± 15 11.5 0.55Ψ 
        RARS/RCMD-RS (29) 20/9 69 ± 11 16.7 0.55 
        5q- syndrome (2) 0/2 70 ± 16 1.1 0 
        MDS-U (15) 9/6 71 ± 8 8.6 0.63Ψ 
    Advanced grade, n = 28: RAEB1/2 16/13 62 ± 14 16.1 1.66 
MDS/MPD, n = 47 
    RARS-T (11) 5/6 70 ± 7 6.3 0.05 
    MDS/MPD-U (12) 7/5 67 ± 7 6.9 0.5 
    CMML1/2 (24) 16/8 66 ± 9 13.8 0.94 
sAML†, n = 33 17/16 68 ± 11 19 2.75* 
Controls, n = 76 32/44 44 ± 19 — — 
CharacteristicsSex (M/F)Age, y (SE)No. (%)IPSS, mean
WHO classification 
MDS, n = 94 
        Low grade, n = 66     
        RA/RCMD (20) 14/6 57 ± 15 11.5 0.55Ψ 
        RARS/RCMD-RS (29) 20/9 69 ± 11 16.7 0.55 
        5q- syndrome (2) 0/2 70 ± 16 1.1 0 
        MDS-U (15) 9/6 71 ± 8 8.6 0.63Ψ 
    Advanced grade, n = 28: RAEB1/2 16/13 62 ± 14 16.1 1.66 
MDS/MPD, n = 47 
    RARS-T (11) 5/6 70 ± 7 6.3 0.05 
    MDS/MPD-U (12) 7/5 67 ± 7 6.9 0.5 
    CMML1/2 (24) 16/8 66 ± 9 13.8 0.94 
sAML†, n = 33 17/16 68 ± 11 19 2.75* 
Controls, n = 76 32/44 44 ± 19 — — 

— indicates not applicable.

†

RAEB-T (FAB) accounts for 15 of 33 secondary AML (WHO).

Ψ

Has patients that cannot be analyzed for IPSS.

*

Only patients with sAML who fulfilled FAB criteria for RAEB-T were included in IPSS analysis.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal